Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Phosphodiesterase type 5 inhibitor (PDE5 inhibitor) is a drug used to block degradation of cgmp-specific phosphodiesterase type 5 (PDE5) loop GMP in smooth muscle cell lining supplying blood vessels to various tissues.These drugs dilate the cavernous penis, promote erections with sexual stimulation, and are used to treat erectile dysfunction (ED).Sildenafil is the first effective oral therapy for ED.Because PDE5 is also present in the wall of the smooth muscle arterioles of the inner lung, sildenafil and tadalafil dilate these vessels and are FDA approved for the treatment of pulmonary hypertension.
Phosphodiesterase Type 5 (PDE5) Inhibitor report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Phosphodiesterase Type 5 (PDE5) Inhibitor market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital and Retail Pharmacy are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Phosphodiesterase Type 5 (PDE5) Inhibitor industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Phosphodiesterase Type 5 (PDE5) Inhibitor key companies include Eli Lilly, Pfizer, Bayer, Novartis AG, Merck, GlaxoSmithKline plc, Roche, AstraZeneca and BaiYunShan General Factory, etc. Eli Lilly, Pfizer, Bayer are top 3 players and held % share in total in 2022.
Phosphodiesterase Type 5 (PDE5) Inhibitor can be divided into Sildenafil, Tadalafil, Avanafil and Vardenafil, etc. Sildenafil is the mainstream product in the market, accounting for % share globally in 2022.
Phosphodiesterase Type 5 (PDE5) Inhibitor is widely used in various fields, such as Hospital, Retail Pharmacy, Online Pharmacies and Other, etc. Hospital provides greatest supports to the Phosphodiesterase Type 5 (PDE5) Inhibitor industry development. In 2022, global % share of Phosphodiesterase Type 5 (PDE5) Inhibitor went into Hospital filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Phosphodiesterase Type 5 (PDE5) Inhibitor market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Eli Lilly
Pfizer
Bayer
Novartis AG
Merck
GlaxoSmithKline plc
Roche
AstraZeneca
BaiYunShan General Factory
SK Chemicals
Teva Pharma
Dong-A ST
Metuchen Pharma
Seoul Pharma
Vectura Group
Segment by Type
Sildenafil
Tadalafil
Avanafil
Vardenafil
Hospital
Retail Pharmacy
Online Pharmacies
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Phosphodiesterase Type 5 (PDE5) Inhibitor market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Phosphodiesterase Type 5 (PDE5) Inhibitor introduction, etc. Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Phosphodiesterase Type 5 (PDE5) Inhibitor market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Phosphodiesterase Type 5 (PDE5) Inhibitor report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Phosphodiesterase Type 5 (PDE5) Inhibitor market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital and Retail Pharmacy are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Phosphodiesterase Type 5 (PDE5) Inhibitor industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Phosphodiesterase Type 5 (PDE5) Inhibitor key companies include Eli Lilly, Pfizer, Bayer, Novartis AG, Merck, GlaxoSmithKline plc, Roche, AstraZeneca and BaiYunShan General Factory, etc. Eli Lilly, Pfizer, Bayer are top 3 players and held % share in total in 2022.
Phosphodiesterase Type 5 (PDE5) Inhibitor can be divided into Sildenafil, Tadalafil, Avanafil and Vardenafil, etc. Sildenafil is the mainstream product in the market, accounting for % share globally in 2022.
Phosphodiesterase Type 5 (PDE5) Inhibitor is widely used in various fields, such as Hospital, Retail Pharmacy, Online Pharmacies and Other, etc. Hospital provides greatest supports to the Phosphodiesterase Type 5 (PDE5) Inhibitor industry development. In 2022, global % share of Phosphodiesterase Type 5 (PDE5) Inhibitor went into Hospital filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Phosphodiesterase Type 5 (PDE5) Inhibitor market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Eli Lilly
Pfizer
Bayer
Novartis AG
Merck
GlaxoSmithKline plc
Roche
AstraZeneca
BaiYunShan General Factory
SK Chemicals
Teva Pharma
Dong-A ST
Metuchen Pharma
Seoul Pharma
Vectura Group
Segment by Type
Sildenafil
Tadalafil
Avanafil
Vardenafil
Segment by Application
Hospital
Retail Pharmacy
Online Pharmacies
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Phosphodiesterase Type 5 (PDE5) Inhibitor market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Phosphodiesterase Type 5 (PDE5) Inhibitor introduction, etc. Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Phosphodiesterase Type 5 (PDE5) Inhibitor market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices